Glomerulonephritis Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about Glomerulonephritis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 3

Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

Kidney DiseasesKidney Diseases, ChronicUrological Diseases+5 more
Novartis Pharmaceuticals220 enrolled6 locationsNCT06858319
Recruiting

The Clinical Application of Artificial Intelligence Assisted Renal Biopsy Diagnosis System.

Chronic Kidney DiseaseChronic Glomerulonephritis
Zhujiang Hospital2,900 enrolled2 locationsNCT07330362
Recruiting
Phase 4

Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?

IgA NephropathyRenal Insufficiency, ChronicIgA Vasculitis+1 more
Christian Medical College, Vellore, India585 enrolled12 locationsNCT06676384
Recruiting

Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)

Kidney DiseasesDiabetic NephropathyKidney Failure, Chronic+2 more
The Rogosin Institute2,000 enrolled1 locationNCT01802034
Recruiting

TESTING -ON Post-Trial ObservatioNal Cohort Study

Kidney DiseasesIgA NephropathyGlomerulonephritis+1 more
The George Institute366 enrolled58 locationsNCT05434325
Recruiting
Phase 3

Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD

Glomerulonephritis, IGA
Air Force Military Medical University, China208 enrolled1 locationNCT05510323
Recruiting

National Registry of Rare Kidney Diseases

Denys-Drash SyndromeTuberous SclerosisAutosomal Recessive Polycystic Kidney Disease+81 more
UK Kidney Association35,000 enrolled1 locationNCT06065852